Go online to PeerView.com/CCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the molecular genetics, cytogenetics, and clinical features of myelofibrosis as well as modern prognostic scoring systems, and their potential impacts on clinical decision-making, Explain the current therapeutic role of JAK inhibitors and emerging novel combination therapies in the management of myelofibrosis, Review the latest clinical evidence supporting the use of first- and second-generation JAK inhibitors and other investigational JAK inhibitor-based combinations in the management of myelofibrosis, Develop individualized, safe, risk-adapted treatment protocols for patients with symptomatic or asymptomatic myelofibrosis, including those with high-risk mutations or who fail prior JAK inhibitor therapy.
View all episodes
